Mahmood, Sajjad

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 785

Defining response to anti-VEGF therapies in neovascular AMD

Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 355

Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis

Sivaprasad, S., Bailey, C., Downey, L., Gilbert, R., Gale, R., Kotagiri, A., Mahmood, S., Morgan-Warren, P., Napier, J., Narendran, N., et al. (2024) · Current Medical Research and Opinion

Health Systems, Economic Evaluations, Quality of LifeRetinal Diseases and Treatments

Cited by 15

Direct Ophthalmic Healthcare Resource Use among Patients with Geographic Atrophy in a Large Cohort from the United Kingdom

Chakravarthy, U., Bailey, C. C., Scanlon, P. H., McKibbin, M., Khan, R. S., Mahmood, S., Downey, L., Dhingra, N., Brand, C., Brittain, C. J., et al. (2019) · Ophthalmology Retina

Retinal Diseases and TreatmentsHealth Systems, Economic Evaluations, Quality of Life

Cited by 11